Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections

Trial Profile

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacterial skin diseases; Gram-positive infections; Skin infections
  • Focus Adverse reactions
  • Sponsors Allergene
  • Most Recent Events

    • 21 Aug 2017 Planned End Date changed from 30 Sep 2018 to 30 Jun 2018.
    • 21 Aug 2017 Planned primary completion date changed from 1 Aug 2018 to 30 Jun 2018.
    • 21 Aug 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top